Kristi Rosa

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.

ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.

Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.

Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

Ficerafusp alfa plus pembrolizumab elicited deep responses in HPV-negative recurrent or metastatic head and neck cancer.

CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.

A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.

EBC-129 has been awarded fast track designation from the FDA for patients with pancreatic ductal adenocarcinoma.

NEOPAN data support the superiority of FOLFIRINOX over gemcitabine in locally advanced pancreatic carcinoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

The FDA has approved belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.

Phase 1 data support further exploration of botensilimab plus balstilimab in patients with hepatocellular carcinoma.

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.